Pumpkinseed Bio

Pumpkinseed Bio focuses on innovative protein analysis through its proprietary DeSIPHR technology. The firm operates independently and has not disclosed any pivots or subsidiary information.Pumpkinseed is at the forefront of protein analysis through its proprietary product, DeSIPHR, which utilizes a nanophotonic chip platform for de novo protein sequencing. This technology allows for direct read-outs of protein identity, sequence, and modification state at single-molecule resolution, leveraging Raman spectroscopy with an unprecedented density of over 100 billion sensors per wafer. The main use cases for DeSIPHR revolve around enhancing drug discovery and development by accelerating target identification and mechanistic studies, as well as uncovering novel protein biomarkers and low-abundance signals that traditional methods often overlook.Pumpkinseed generates revenue through partnerships with biopharma firms, research institutions, and other entities involved in drug development and biological research. The company engages in B2B transactions, providing access to its DeSIPHR platform as a subscription service or through bespoke arrangements based on client needs. This revenue model includes licensing agreements, where clients pay for the usage of the technology in their proprietary research, alongside potential service fees for data analysis and interpretation. Specific plans for new products or geographic expansion have not been disclosed, but the emphasis will be on fostering growth and enhancing product offerings to better serve the biopharma market.

1. Series A

   May 5, 2026

   Amount

   $20M

   Investors

   Locked